CN113712982B - 一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用 - Google Patents
一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用 Download PDFInfo
- Publication number
- CN113712982B CN113712982B CN202111070083.8A CN202111070083A CN113712982B CN 113712982 B CN113712982 B CN 113712982B CN 202111070083 A CN202111070083 A CN 202111070083A CN 113712982 B CN113712982 B CN 113712982B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- composition
- isoquercitrin
- obesity
- fatty liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract description 20
- 208000008589 Obesity Diseases 0.000 title abstract description 14
- 235000020824 obesity Nutrition 0.000 title abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 82
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 claims abstract description 51
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 claims abstract description 50
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims abstract description 50
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 41
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 41
- 239000011718 vitamin C Substances 0.000 claims abstract description 41
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 claims abstract description 37
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 claims abstract description 13
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 230000036541 health Effects 0.000 abstract description 5
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 238000000354 decomposition reaction Methods 0.000 abstract description 3
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 3
- 239000000194 fatty acid Substances 0.000 abstract description 3
- 229930195729 fatty acid Natural products 0.000 abstract description 3
- 150000004665 fatty acids Chemical class 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 25
- 235000009200 high fat diet Nutrition 0.000 description 24
- 210000004185 liver Anatomy 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 20
- 230000037396 body weight Effects 0.000 description 11
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 2
- OVSQVDMCBVZWGM-LQSBFMDOSA-N 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-LQSBFMDOSA-N 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000020166 milkshake Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001329 FEMA 3811 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000062 effect on obesity Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 1
- 235000010434 neohesperidine DC Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Botany (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于医药保健品技术领域，公开了一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用，该组合物包括组分：异槲皮素和维生素C，异槲皮素和维生素C的质量比为0.1‑2:1。本发明组合物通过异槲皮素和维生素C按照特定比例进行复配，其中维生素C促进脂肪代谢，加速脂肪分解，异槲皮素可以将脂肪酸快速氧化，同时减少脂质的生成，异槲皮素和维生素C能够起到协同增效作用，对肥胖症和非酒精性脂肪肝的疗效显著。
Description
技术领域
本发明属于医药保健品技术领域，特别涉及一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用。
背景技术
肝脏是机体脂质代谢的中心器官，肝内脂肪主要来源于食物和外周脂肪组织，脂类物质在肝脏内蓄积超过肝脏重量的5％，或在组织学上50％以上的肝实质脂肪化时，即为脂肪肝。脂肪肝的主要形成原因有肥胖，酒精中毒，糖尿病，营养失调，药物中毒，妊娠，遗传等原因。
目前，在全球普通人群中非酒精性脂肪性肝病患病率高达20％-30％，世界范围内超过一半的人将有发生非酒精性脂肪性肝病的危险，明显超过乙型肝炎、丙型肝炎及酒精性肝病的发病率，已成为最常见的肝病。流行病学调查显示非酒精性脂肪肝在一些发达地区的成人患病率达10％-25％，且渐趋低龄化。脂肪肝可在短期内发展为不可逆的肝损伤，其纤维化的发生率高达25％，且约有10％的患者会发展为肝硬化，严重威胁人类的健康。对非酒精性脂肪肝的治疗临床上尚缺乏疗效确切的特效药。
现有相关技术公开了一种治疗脂肪肝、肥胖症的中药提取物及其制备方法。其有效成分有木犀草素、芹菜素、槲皮素、芦丁、异槲皮素、杨梅素、异鼠李素、黄芪皂苷。其评价效果是总的提取物的药效，组分非常复杂，没有对单一物质进行评价，不能明确指出是哪种物质起作用，副作用有待商榷，且提取制备工艺复杂。
发明内容
本发明旨在至少解决上述现有技术中存在的技术问题之一。为此，本发明提出一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用；本发明提供的组合物对肥胖症和非酒精性脂肪肝的疗效显著。
本发明的第一方面提供一种预防或治疗非酒精性脂肪肝、肥胖症的组合物，包括组分：异槲皮素和维生素C，所述异槲皮素和所述维生素C的质量比为0.1-2:1。
本发明申请人在研究中发现，异槲皮素通过促进脂肪酸的氧化、减少脂质的生成、抑制脂肪细胞的分化和促进脂肪的褐色变，从而降低肠系膜，附睾和皮下脂肪的重量，达到减肥的效果，并且可以通过促进肌肉葡萄糖的转化吸收，提高胰岛素拮抗来调节血糖水平，起到降血糖的作用。维生素C可以合成肉碱并刺激甲肾上腺素，肉碱能够促进脂肪的新陈代谢，加速脂肪和类脂的分解和燃烧，而肾上腺素能够调节心情，抑制大脑的食欲。
本发明组合物通过异槲皮素和维生素C按照特定比例进行复配，其中维生素C促进脂肪代谢，加速脂肪分解，异槲皮素可以将脂肪酸快速氧化，同时减少脂质的生成，异槲皮素和维生素C能够起到协同增效作用，对肥胖症和非酒精性脂肪肝的疗效显著。
需要说明的是，本发明也可以采用以异槲皮素为活性成分进行改性做成的物质，例如以异槲皮素为活性物质，将异槲皮素经过糖基化，包埋，成盐或乳化等形式制备成的物质，在该物质中，异槲皮素占总重的百分比含量为1-99％。
优选地，所述异槲皮素和所述维生素C的质量比为0.1-1:1。
优选地，所述异槲皮素的人用剂量为0.2-0.4g/天。
优选地，所述维生素C的人用剂量为0.2-1.5g/天。
本发明的第二方面提供所述组合物的制备方法，包括以下步骤：
将所述异槲皮素和所述维生素C混合，得到所述组合物。
本发明的第三方面提供所述组合物在制备治疗或预防非酒精性脂肪肝、肥胖症的食品、药品和/或保健品中的应用。
优选地，所述药品或保健品的剂型为片剂、胶囊剂、颗粒剂、粉剂或口服液。
根据上述应用，本发明提供了一种保健品，包括本发明所述组合物和保健品上可接受的辅料。同时还提供了一种药品，包括本发明所述组合物和药品上可接受的辅料。另外还提供了一种食品，包括本发明所述组合物和食品上可接受的辅料。
相对于现有技术，本发明的有益效果如下：
本发明所述组合物包括异槲皮素和维生素C，各组分合理配伍产生增效协同作用，能够显著降低小鼠的肝功能指标如ALP(碱性磷酸酶)，ALT(谷丙转氨酶)和AST(谷草转氨酶)。本发明组合物组分简单，安全性高，无毒副作用，显效快，疗效明确。
附图说明
图1为试验例对小鼠体重变化的检测结果图。
图2为试验例对小鼠肝脏重量变化、肝重与体重的比值的检测结果图。
图3为试验例对小鼠肝功能碱性磷酸酶、谷丙转氨酶和谷草转氨酶含量的检测结果图。
具体实施方式
为了让本领域技术人员更加清楚明白本发明所述技术方案，现列举如下实施例进行说明。需要指出的是，如下实施例对本发明要求的保护范围不构成限制作用。
如下实施例中所用的组分、试剂或装置如无特殊说明，均可从常规商业途径得到，或者可以通过现有已知方法得到。
实施例1
一种预防或治疗非酒精性脂肪肝、肥胖症的组合物，包括组分：异槲皮素和维生素C；异槲皮素和维生素C的质量比为2:1。
实施例2
一种预防或治疗非酒精性脂肪肝、肥胖症的组合物，包括组分：异槲皮素和维生素C；异槲皮素和维生素C的质量比为1:1。
实施例3
一种预防或治疗非酒精性脂肪肝、肥胖症的组合物，包括组分：异槲皮素和维生素C；异槲皮素和维生素C的质量比为0.1:1。
对比例1
与实施例1的区别在于，对比例1中不含有维生素C。
对比例2
与实施例1的区别在于，对比例2中不含有异槲皮素。
对比例3
与实施例1的区别在于，对比例3中将异槲皮素替换为槲皮素。
对比例4
与实施例1的区别在于，对比例4中将维生素C替换为维生素B。
对比例5
与实施例1的区别在于，对比例5中将维生素C替换为维生素E。
对比例6
与实施例1的区别在于，对比例6中异槲皮素和维生素C的质量比为3:1。
对比例7
与实施例1的区别在于，对比例7中异槲皮素和维生素C的质量比为0.05:1。
实施例4
一种胶囊剂，其组分包括：异槲皮素99％0.2克，维生素C 0.2克，淀粉0.1克。将各组分进行混合制粒，过筛，装胶囊，做成胶囊剂。
实施例5
一种片剂，其组分包括：糖基化异槲皮素(异槲皮素的质量含量为50％)0.5克，维生素 C 0.8克，硬脂酸镁0.3克。将各组分进行混合，计算片重，压片可得。
实施例6
一种软糖，其组分包括：白砂糖20克、糖浆40克、干明胶6克、环糊精包埋异槲皮素100克(异槲皮素的质量含量为1％)，维生素C 2克，柠檬酸0.7克，柠檬酸钠0.07克。按照软糖常规制作工艺制作而成。
实施例7
一种奶昔，其组分包括：白沙糖20克，新橙皮苷二氢查尔酮0.03克，抗性糊精20克，磷脂包埋异槲皮素3克(异槲皮素的质量含量为20％)，维生素C 3克，脱脂奶粉40克大豆分离蛋白20克，柑橘纤维10克，羧甲基纤维素0.5克。按照常规方法，将各组分进行混合制备而成奶昔。
试验例
1.分组与喂养
雄性C57BL6小鼠(6-8周)，并在23.2℃下进行12小时的光-暗循环。经过一周的适应后，小鼠随机分为12组(n＝12，5只/笼)，分别按照如下组进行喂养，期间小鼠被允许随意获得水和食物，小鼠以各自的饮食维持15周。
1组：正常饲料，2组：高脂肪饲料，3组：高脂肪饲料+实施例1的样品(异槲皮素、维生素C分别占高脂肪饲料0.1wt％、0.05wt％)，4组：高脂肪饲料+实施例2的样品(异槲皮素、维生素C分别占高脂肪饲料0.05wt％、0.05wt％)，5组：高脂肪饲料+实施例3的样品(异槲皮素、维生素C分别占高脂肪饲料0.005wt％、0.05wt％)，6组：高脂肪饲料+对比例 1的样品(异槲皮素占高脂肪饲料0.1wt％)，7组：高脂肪饲料+对比例2的样品(维生素C 占高脂肪饲料0.05wt％)，8组：高脂肪饲料+对比例3的样品(槲皮素、维生素C分别占高脂肪饲料0.1wt％、0.05wt％)，9组：高脂肪饲料+对比例4的样品(异槲皮素、维生素B分别占高脂肪饲料0.1wt％、0.05wt％)，10组：高脂肪饲料+对比例5的样品(异槲皮素、维生素E分别占高脂肪饲料0.1wt％、0.05wt％)，11组：高脂肪饲料+对比例6的样品(异槲皮素、维生素C分别占高脂肪饲料0.15wt％、0.05wt％)，12组：高脂肪饲料+对比例7的样品(异槲皮素、维生素C分别占高脂肪饲料0.0025wt％、0.05wt％)。
其中，正常饲料为市售商品鼠粮，脂肪含量为5％，蛋白质为25％，碳水化合物为65％，粗纤维为5％。高脂肪饲料包含20％脂肪，0.2％胆固醇，24.8％蛋白质，50％碳水化合物(含35％蔗糖)和5％粗纤维。上述饲料各组分含量均为质量百分比含量。
2.观察，检测，记录
每周测量体重和食物摄入量，每日观察小鼠食欲、排便、尿液、活动等情况，每周记录小鼠体重，绘制小鼠体重变化曲线。15周后对小鼠血清进行检测。处死小鼠摘取肝脏，称重，记录肝脏的重量。
血清中的碱性磷酸酶、谷丙转氨酶、谷草转氨酶，检测方法按照试剂盒的说明书来完成。
3.试验结果
从图1可以看出，2组由于喂养高脂肪饲料，导致小鼠的体重明显增加。3-5组在高脂肪饲料的基础上，分别添加实施例1-3的组合物，与2组相比，小鼠的体重得到明显降低，说明本发明组合物具有显著的减肥效果。6-10组在高脂肪饲料的基础上，分别添加对比例1-5 的组合物，与2组相比，小鼠的体重有所降低，但是效果并不明显，说明本发明组合物将异槲皮素和维生素C复配，具有协同增效的作用，能够显著降低小鼠的体重。11-12组在高脂肪饲料的基础上，分别添加对比例6-7的组合物，与2组相比，小鼠的体重有所降低，但是效果低于3-5组，说明本发明组合物将异槲皮素和维生素C按照特定的比例复配，能够发挥最佳效用，显著降低小鼠的体重。
从图2可以看出，2组由于喂养高脂肪饲料，导致小鼠的肝脏重量以及肝脏重量和体重的比值明显增加。3-5组在高脂肪饲料的基础上，分别添加实施例1-3的组合物，与2组相比，小鼠的肝脏重量以及肝脏重量和体重的比值得到明显降低，说明本发明组合物具有显著的降低肝细胞内脂肪含量的效果。6-10组在高脂肪饲料的基础上，分别添加对比例1-5的组合物，与2组相比，小鼠的肝脏重量以及肝脏重量和体重的比值有所降低，但是效果并不明显，说明本发明组合物将异槲皮素和维生素C复配，具有协同增效的作用，能够显著降低小鼠的肝脏重量以及肝脏重量和体重的比值。11-12组在高脂肪饲料的基础上，分别添加对比例6-7的组合物，与2组相比，小鼠的肝脏重量以及肝脏重量和体重的比值有所降低，但是效果低于 3-5组，说明本发明组合物将异槲皮素和维生素C按照特定的比例复配，能够发挥最佳效用，显著降低小鼠的肝脏重量以及肝脏重量和体重的比值。
对小鼠肝功能进行检测，从图3可以看出，3-5组在高脂肪饲料的基础上，分别添加实施例1-3的组合物，与2组相比，肝功能指标ALP(碱性磷酸酶)，ALT(谷丙转氨酶)和AST(谷草转氨酶)，均得到显著降低，治疗效果接近于1组。而6-10组的效果并不明显，说明本发明组合物将异槲皮素和维生素C复配，具有协同增效的作用，对长期高脂饮食小鼠的肝脏具有很好的保护作用，能够起到防止肝损伤的作用。11-12组的效果也低于3-5组，说明本发明组合物将异槲皮素和维生素C按照特定的比例复配，能够发挥最佳效用，显著降低肝功能指标。
以上对本发明的较佳实施方式进行了具体说明，但本发明创造并不限于所述实施例，熟悉本领域的技术人员在不违背本发明精神的前提下还可作出种种的等同变型或替换，这些等同的变型或替换均包含在本申请权利要求所限定的范围内。
Claims (5)
1.一种组合物作为仅有的活性成分在制备治疗或预防非酒精性脂肪肝的药品中的应用，所述组合物由异槲皮素和维生素C组成，所述异槲皮素和所述维生素C的质量比为0.1-2:1。
2.根据权利要求1所述的应用，其特征在于，所述异槲皮素和所述维生素C的质量比为0.1-1:1。
3.根据权利要求1所述的应用，其特征在于，所述异槲皮素的人用剂量为 0.2-0.4g/天。
4.根据权利要求1所述的应用，其特征在于，所述维生素C的人用剂量为 0.2-1.5g/天。
5.根据权利要求1所述的应用，其特征在于，所述药品的剂型为片剂、胶囊剂、颗粒剂、粉剂或口服液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111070083.8A CN113712982B (zh) | 2021-09-13 | 2021-09-13 | 一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111070083.8A CN113712982B (zh) | 2021-09-13 | 2021-09-13 | 一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113712982A CN113712982A (zh) | 2021-11-30 |
| CN113712982B true CN113712982B (zh) | 2022-12-06 |
Family
ID=78683563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111070083.8A Active CN113712982B (zh) | 2021-09-13 | 2021-09-13 | 一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113712982B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6491948B1 (en) * | 1999-03-16 | 2002-12-10 | Merck Patent Gmbh | Composition comprising isoquercetin and ascorbic acid in a sustained release form |
| US7041652B1 (en) * | 1998-08-27 | 2006-05-09 | Merck Patent Gmbh | Ascorbate-isoquercetin compositions |
| JP2014097987A (ja) * | 2013-12-17 | 2014-05-29 | Shizuokaken Koritsu Daigaku Hojin | 内臓脂肪蓄積抑制剤 |
| KR20170023910A (ko) * | 2017-02-22 | 2017-03-06 | 가톨릭대학교 산학협력단 | 퀘르세틴-3-o-글루코시드를 포함하는 비알콜성 지방간 예방 또는 치료용 약학적 조성물 |
| CN108135952A (zh) * | 2015-09-23 | 2018-06-08 | 瑞奥克辛创新集团有限责任公司 | 类黄酮组合物及其使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6445850B2 (ja) * | 2014-11-17 | 2018-12-26 | サントリーホールディングス株式会社 | 酵素処理イソクエルシトリン含有容器詰飲料 |
| CN109700797B (zh) * | 2017-10-25 | 2021-06-15 | 南京葆赫生物技术有限公司 | 一种减肥的药物组合物及其制备方法与用途 |
-
2021
- 2021-09-13 CN CN202111070083.8A patent/CN113712982B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041652B1 (en) * | 1998-08-27 | 2006-05-09 | Merck Patent Gmbh | Ascorbate-isoquercetin compositions |
| US6491948B1 (en) * | 1999-03-16 | 2002-12-10 | Merck Patent Gmbh | Composition comprising isoquercetin and ascorbic acid in a sustained release form |
| JP2014097987A (ja) * | 2013-12-17 | 2014-05-29 | Shizuokaken Koritsu Daigaku Hojin | 内臓脂肪蓄積抑制剤 |
| CN108135952A (zh) * | 2015-09-23 | 2018-06-08 | 瑞奥克辛创新集团有限责任公司 | 类黄酮组合物及其使用方法 |
| KR20170023910A (ko) * | 2017-02-22 | 2017-03-06 | 가톨릭대학교 산학협력단 | 퀘르세틴-3-o-글루코시드를 포함하는 비알콜성 지방간 예방 또는 치료용 약학적 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113712982A (zh) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6932990B2 (en) | Carbohydrate absorption inhibitor and method for manufacturing the same | |
| EP0815857B1 (en) | Antiobestic agent containing procyanidin as the active ingredient | |
| JPH09291039A (ja) | プロシアニジンを有効成分とする抗肥満剤 | |
| US6280776B1 (en) | Composition comprising Panax pseudo ginseng and Eucommiae ulmoides | |
| WO2011077800A1 (ja) | 高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品 | |
| CN106074971A (zh) | 一种降血糖中药组合物及制备方法与应用 | |
| TWI269656B (en) | Therapeutical composition for hepatitis C | |
| CN103445175B (zh) | 具有解酒保肝作用的组合物 | |
| JP5002127B2 (ja) | アカシア属樹皮由来物を含有する血糖降下組成物 | |
| CN104644734B (zh) | 一种治疗ⅱ型糖尿病及其并发症的药物 | |
| CN113712982B (zh) | 一种预防或治疗非酒精性脂肪肝、肥胖症的组合物及制备方法和应用 | |
| CN108420890B (zh) | 一种具有降血脂作用的组合物及其制备方法 | |
| JP2004149471A (ja) | 血糖低下剤 | |
| JP3433917B2 (ja) | 体タンパク質蓄積効率を亢進する栄養組成物 | |
| KR100293890B1 (ko) | 동아녹즙및그잔사를사용하여제조된체중및혈당조절용식품조성물및그제조방법 | |
| JP2002173435A (ja) | 抗肥満剤および当該抗肥満剤の投与方法 | |
| WO2017186954A1 (en) | Method for the improvement of speed and endurance capacity | |
| JP2001048794A (ja) | 桑の葉由来粉末およびカキ由来粉末の混合物を含むｎｉｄｄｍ治療用の医薬組成物および健康食品 | |
| CN108904596B (zh) | 一种具有改善记忆力功效的组合物 | |
| CN106349318A (zh) | 一种五环三萜化合物在制备治疗肥胖症药物中的应用 | |
| JP4610730B2 (ja) | カルシウム補給用の組成物 | |
| JP2009062348A (ja) | ケナフ類（ケナフ、ローゼル）の種子成分による血糖値低下作用及び血糖値上昇抑制作用 | |
| JP4524018B2 (ja) | 桑の葉およびアガリクス抽出混合物を含むインスリン非依存型糖尿病の予防、治療用の医薬組成物および健康食品 | |
| CN110404029B (zh) | 一种具有降血糖功效的组合物及其制备方法和应用 | |
| JP6437183B2 (ja) | 肝機能改善剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A composition, preparation method, and application for preventing or treating non-alcoholic fatty liver and obesity Granted publication date: 20221206 Pledgee: Guangdong Nanhai rural commercial bank Limited by Share Ltd. Sanshui branch Pledgor: GOLDEN HEALTH BIOTECHNOLOGY Co.,Ltd. Registration number: Y2024980021086 |